Evolving Real-Time Continuous Glucose Monitoring Use in the Hospital: Where Are We Now?
This continuing medical education activity is supported by an independent educational grant from Dexcom.
This activity is intended for hospitalists and other hospital-based clinicians who treat patients with diabetes.
The goal of this activity is that learners will be better able to understand why and how real-time continuous glucose monitoring (rtGCM) can be used in the hospital setting, including in the non-intensive care unit (ICU) setting, the ICU setting, and the stepdown unit.
Upon successful completion of this activity, participants should:
- Have increased knowledge regarding the
- Data supporting use of rtCGM in various hospital settings
- Best practices for implementing rtCGM as part of standard of care in the hospital
CONFLICT OF INTEREST POLICY/DISCLOSURE STATEMENT
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
Anne G. Le, PharmD
Senior Medical Education Director, Medscape, LLC
Disclosure: Anne G. Le, PharmD, has no relevant financial relationships.
Amanda Jett, PharmD, BCACP
Associate Director, Accreditation and Compliance, Medscape, LLC
Disclosure: Amanda Jett, PharmD, BCACP, has no relevant financial relationships.
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
This enduring material is approved for 1 year from the date of original release, May 12, 2022, to May 12, 2023.
This activity is accredited through Medscape. Click the link below to claim credit. You will be prompted to create a Medscape account and complete the post-test. If a satisfactory score on the post-test is achieved, Medscape will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Kathleen M. Dungan, MD, MPH
Professor of Medicine
The Ohio State University
Division of Endocrinology
Diabetes & Metabolism
Kathleen M. Dungan, MD, MPH, has the following relevant financial relationships:
- Consultant or advisor for: Boehringer Ingelheim; Dexcom; Eli Lilly; Novo Nordisk; Tolerion
- Research funding from: Abbott; Dexcom; Novo Nordisk; Sanofi; ViaCyte